Role of complement and Fc receptors in the pathogenesis of HIV-1 infection

Springer Seminars in Immunopathology

Volumn 18, Issue 3, 1997, Pages 371-390

  Montefiori, David C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; FC RECEPTOR;

ARTICLE; B LYMPHOCYTE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS PATHOGENESIS;

B-LYMPHOCYTES; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOID TISSUE; RECEPTORS, COMPLEMENT 3D; RECEPTORS, FC; VIRUS REPLICATION;

EID: 0031054248     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00813504     Document Type: Article

References (176)

1. Ahearn JM, Fearon DT (1989) Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 46:183
2. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Nystrom G, Fenyo EM (1990) Rapid development of isolate-specific neutralizing antibodies after primary HIV-1-infection and consequent emergence of virus variants which resist neutralization by autologous sera. J Acquir Immune Defic Syndr 4:107
3. Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, Rosen CA, Haseltine WA, Lee TH, Essex M (1985) Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091
4. Arthur LO, Bess JW, Sowder RC, Benveniste RE, Mann DL, Chermann J-C, Henderson LE (1991) Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258:1935
5. Ashwell JD (1988) Are B lymphocytes the principal antigen-presenting cells in vivo? J Immunol 140:3697
6. Bakker LJ, Nottet HSLM, Vos NM de, Graaf L de, Strijp JAG van, Visser MR, Verhoef J (1992) Antibodies and complement enhance binding and uptake of HIV-1 by human monocytes. J Acquir Immune Defic Syndr 6:35
7. Banapour B, Sernatinger J, Levy JA (1986) The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 152:268
8. Bender BS, Davidson BL, Kline R, Brown C, Quinn TC (1988) Role of the mononuclear phagocytic system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev Infect Dis 10:1142
9. Beral V, Peterman T, Berkelman R, Jaffe H (1991) AIDS-associated non-Hodgkin lymphoma. Lancet 337:805
10. Bohnsack JF, Cooper NR (1988) CR2 ligands modulate human B cell activation. J Immunol 141:2569
11. Bolognesi DP (1989) Do antibodies enhance the infection of cells by HIV? Nature 340:431
12. - and antibody-independent fashion. J Exp Med 173:1151
13. Boyer V, Delibrias C, Noraz N, Fischer E, Kazatchkine MD, Desgranges C (1992) Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scan J Immunol 36:879
14. Burke SB (1992) Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med 35:511
15. Carter RH, Fearon DT (1989) Polymeric C3dg primes human lymphocytes for proliferation induced by anti-IgM. J Immunol 143:1755
16. Carter RH, Fearon DT (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105
17. Carter RH, Spycher MO, Ng YC, Hoffman R, Fearon DT (1988) Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol 141:457
18. Chiodi F, Mathiesen T, Albert J, Parks E, Norrby E, Wahren B (1989) IgG subclass responses to a transmembrane protein (gp41) peptide in HIV infection. J Immunol 142:3809
19. Clark SJ, Saag MS, Decke WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC, Hahn BH, Shaw GM (1991) High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 324:954
20. Cohen JHM, Aubry JP, Revillard JP, Banchereau J, Kazatchkine MD (1989) Human T lymphocytes expressing the C3b/C4b complement receptor type one (CR1, CD35) belong to Fcγ receptor-positive CD4-positive T cells. Cell Immunol 121:383
21. Connor RI, Dinces NB, Howell AL, Romet-Lemonne J-L, Pasquali J-L, Fanger MW (1991) Fc receptors for IgG (FcγRs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including FcγR. Proc Natl Acad Sci USA 88:9593
22. Cranage MP, Polyanskaya N, McBride B, Cook N, Ashworth LAE, Dennis M, Baskerville A, Greenaway PJ, Corcoran T, Kitchen P, Rose J, Murphey-Corb M, Desrosiers RC, Stott EJ, Farrar GH (1993) Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses 9:13
23. Daar ES, Moudgil T, Meyer RD, Ho DD (1991) Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 324:961
24. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763
25. Daniel V, Susal C, Weimer R, Zimmerman R, Huth-Kuhne A, Opelz G (1993) Association of T cell and macrophage dysfunction with surface gp120-immunoglobulin-complement complexes in HIV-infected patients. Clin Exp Med 93:152
26. Delibrias C-C, Mouhoub A, Fischer E, Kazatchkine MD (1994) CR1 (CD35) and CR2 (CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur J Immunol 24:2784
27. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348
28. Dolin R, Graham BS, Greenberg SB, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablien DM, Smith GE, Koff WC, the NIAID AIDS Vaccine Clinical Trials Network (1991) The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 114:119
29. Eaton AM, Ugen KE, Weiner DB, Wildes T, Levy JA (1994) An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Res Hum Retroviruses 10:13
30. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP (1991) Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 174:1417
31. Erdie A, Fust G, Gergely J (1991) The role of C3 in the immune response. Immunol Today 12:332
32. Fanger MW, Shen L, Graziano RF, Guyre PM (1989) Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 10:92
33. Fearon DT (1978) Regulation of membrane sialic acid of B1H-dependent decay dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 75:1971
34. Fiscus SA, Folds JD, Horst CM van der (1993) Infectious immune complexes in HIV-1-infected patients. Viral Immunol 6:135
35. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM (1986) Glycoprotein C of Herpes simplex virus type 1 is an inhibitor of the complement cascade. J Immunol 137:1636
36. Geyer H, Holschbach C, Hunsman C, Schneider J (1988) Carbohydrates of human immunodeficiency virus: structures of oligosaccharides linked to the envelope glycoprotein gp120. J Biol Chem 263:11760
37. Graham, BS, Wright PF (1995) Candidate AIDS Vaccines. N Engl J Med 333:1331
38. Gras GS, Dormont D (1991) Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. J Virol 65:541
39. Gras G, Richard Y, Roques P, Olivier R, Dormont D (1993) Complement and virus-specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. Blood 81:1808
40. Gray D, Skarvall H (1988) B-cell memory is short-lived in the absence of antigen. Nature 336:70
41. + T cell clones. Eur J Immunol 24:2982
42. Halstead SB (1982) Immune enhancement of viral infection. Prog Allergy 31:301
43. Harada S, Yoshiyama H, Yamamoto N (1985) Effect of heat and fresh human serum on the infectivity of human T cell lymphotropic virus type III evaluated with new bioassay systems. J Clin Microbiol 22:908
44. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC (1993) Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. J Acquir Immune Defic Syndr 7:1307
45. Heath SL, Tew JG, Tew JG, Szakal AK, Burton GF (1995) Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377:740
46. Hebell T, Ahearn JM, Fearon DT (1991) Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254:102
47. Heyman B, Wiersma EJ, Kinoshita T (1991) In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med 172:665
48. Hirsch RL (1982) The complement system: its importance in the host response to viral infection. Microbiol Rev 46:71
49. Hirsch RL, Wolinsky JS, Winkelstein JA (1986) Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity. Arch Virol 87:181
50. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1-infection. Nature 373:123
51. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S-O, Gingrich JB, Latendresse J, Fukai K, Burke DS (1988) Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319:608
52. Homsy J, Meyer M, Tateno M, Clarkson S, Levy JA (1989) The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244:1357
53. Homsy J, Meyer M, Levy JA (1990) Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol 64:1437
54. Inada Y, Lange M, McKinley GF, Sonnabend JA, Fonville TW, Kanemitsu T, Tanaka M, Clark WS (1986) Hematologic correlates and the role of erythrocyte CR1 (C3b receptors) in the development of AIDS. AIDS Res 2:235
55. Jacob J, Kelsoe G, Rajewsky K, Weiss U (1991) Intraclonal generation of antibody mutants in germinal centres. Nature 354:389
56. Joling P, Bakker LJ, Van Strijp JAG, Meerloo T, Graaf L de, Dekker MEM, Goudsmit J, Verhoef J, Schuurman H-J (1993) Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol 150:1065
57. Jouault T, Chapuis F, Olivier R, Parravicini C, Bahraoui E, Gluckman J-C (1989) HIV infection of monocytic cells: role of antibody-mediated virus binding to Fcγ receptors. AIDS 3:125
58. Jouvin M-H, Rozenbaum W, Russo R, Kazatchkine MD (1987) Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. J Acquir Immune Defic Syndr 1:89
59. June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, Landay AL, Spear GT (1991) Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. J Acquir Immune Defic Syndr 5:269
60. + cells in HIV-infected persons. Immunology 75:59
61. Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath J, Clements ML, Gorse GJ, Wright PF, Matthews TJ, Smith GE, Lawrence D, Dolin R, the NIAID AIDS Vaccine Clinical Trials Network (1994) Studies of high doses of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in HIV-1 seronegative humans. AIDS Res Hum Retroviruses 10:1713
62. Khalife J, Guy B, Capron M, Kieny M-P, Ameisen J-C, Montagnier L, Lecocq J-P, Capron A (1988) Isotypic restriction of antibody response to human immunodeficiency virus. AIDS Res Hum Retroviruses 4:3
63. Kinoshita T (1991) Biology of complement: the overture. Immunol Today 12:291
64. Klasse PJ, Blomberg J (1987) Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG. J Infect Dis 156:1026
65. Klaus GGB, Humphrey JH, Kunkle A, Dongworth DW (1980) The follicular dendritic cell: its role in antigen presentation in the generation of immunological memory. Immunol Rev 53:3
66. Kliks SC, Shioda T, Haigwood NL, Levy JA (1993) V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90:11518
67. Kobayashi K, Takeda A, Green S, Tuazon CU, Ennis FA (1993) Direct detection of infectious human immunodeficiency virus type 1 (HIV-1) immune complexes in the sera of HIV-1-infected persons. J Infect Dis 168:729
68. Kornfeld R, Kornfeld S (1985) Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54:631
69. Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, Moss B (1990) Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250:827
70. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen C, Haseltine W, Sodroski J (1987) Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237:1351
71. Kozlowski PA, Black KP, Shen L, Jackson S (1995) High prevalence of serum IgA HIV-1-infection-enhancing antibodies in HIV-infected persons. J Immunol 154:6163
72. Lachman PJ (1991) The control of homologous lysis. Immunol Today 12:312
73. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP (1992) Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses 8:1641
74. Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P, Gregory T, Capon DJ (1987) Delineation of a region of the human immunodeficiency virus gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50:975
75. Laurence J, Saunders A, Early E, Salmon JE (1990) Human immunodeficiency virus infection of monocytes: relationship to Fcγ receptors and antibody-dependent viral enhancement. Immunol 70:338
76. Lederman MM, Purvis SF, Walter EI, Carey JT, Medof ME (1989) Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-acelerating factor. Proc Natl Acad Sci USA 86:4205
77. Liu Y-J, Johnson GD, Gordon J, MacLennan ICM (1992) Germinal centres in T cell-dependent antibody responses. Immunol Today 13:17
78. Luxembourg AT, Cooper NR (1994) Modulation of signaling via the B cell antigen receptor by CD21, the receptor for C3dg and EBV. J Immunol 153:4448
79. Mabondzo A, Aussage P, Bartholeyns J, Le Naour R, Raoul H, Romet-Lemonne J-L, Dormont D (1992) Bispecific antibody targeting of human immunodeficiency virus type 1 (HIV-1) glycoprotein 41 to human macrophages through the Fc IgG receptor I mediates neutralizing effects in HIV-1-infection. J Infect Dis 166:93
80. Mann DL, Hamlin-Green G, Willoughby A, Landesman SH, Goedert, JJ (1994) Immunoglobulin class and subclass antibodies to HIV proteins in maternal serum: association with perinatal transmission. J Acquir Immune Defic Syndr 7:617
81. Marschang P, Gurtler L, Totsch M, Thielens NM, Arlaud GJ, Hittmair A, Katinger H, Dierich MP (1993) HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. J Acquir Immune Defic Syndr 7:903
82. Marschang P, Sodroski J, Wurzner R, Dierich MP (1995) Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 25:285
83. Martinez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV (1987) Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 138:3720
84. Mascola JR, Matthieson BJ, Zack PM, Walker MC, Halstead SB, Burke DS (1993) Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses 9:1175
85. Matsumoto AK, Kopicky-Burd J, Carter RH, Tuveson DA, Tedder TF, Fearon DT (1991) Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med 173:55
86. McClure MO, Marsh M, Weiss RA (1987) Human immunodeficiency virus type 1 infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J 7:513
87. McHugh TM, Stites DP, Busch MP, Krowka JF, Stricker RB, Hollander H (1988) Relation of circulating levels of human immunodeficiency virus (HIV) antigen, antibody to p24, and HIV-containing immune complexes in HIV-infected patients. J Infect Dis 158:1088
88. McSharry JJ, Pickering RJ, Caliguiri LA (1981) Activation of the alternate complement pathway by enveloped viruses containing limited amounts of sialic acid. Virology 114:507
89. Melchers F, Erdei A, Schultz T, Dierich MP (1985) Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature 317:264
90. Mizouchi T, Spellman MW, Larkin M, Solomon J, Basa LJ, Feizi T (1988) Carbohydrate structures of the human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biochem J 254:599
91. Montefiori DC (1995) New insights into the role of host cell proteins in antiviral vaccine protection. AIDS Res Hum Retroviruses 11:1429
92. Montefiori DC (1996) Role of complement in HIV and SIV pathogenesis and immunity. In: Eible MM, Huber C, Peter HH, Wahn U (eds) Symposium in Immunology. V Antiviral Immunity. Springer, Heidelberg Berlin New York, pp 31-53
93. Montefiori DC, Robinson WE, Mitchell WM (1989) Antibody-independent, complement-mediated enhancement of HIV-1-infection by mannosidase I and II inhibitors. Antiviral Res 11:137
94. Montefiori DC, Robinson WE Jr, Hirsch VM, Modliszewski A, Mitchell WM, Johnson PR (1990) Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus monkeys. J Virol 64:113
95. Montefiori DC, Lefkowitz LB, Keller RE, Holmberg V, Sandstrom E, Phair JP, the Multicenter AIDS Cohort Study Group (1991) Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma and sera from HIV-1 infected persons. J Acquir Immune Defic Syndr 5:513
96. Montefiori DC, Graham BS, Kliks S, Wright PF, the NIAID AIDS Vaccine Clinical Trials Nework (1992) Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J Clin Immunol 12:429
97. Montefiori DC, Zhou J, Shaff DI (1992) CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. Clin Exp Immunol 90:383
98. Montefiori DC, Stewart K, Ahearn JM, Zhou JT, Zhou JY (1993) Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J Virol 67:2699
99. Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR (1994) Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205:82
100. Montefiori DC, Graham BS, Zhou JY, Zhou JT, Ahearn JM (1994) Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor, CR1 (CD35), and red blood cells in the presence of envelope-specific antibodies and complement. J Infect Dis 170:429
101. Montefiori DC, Reimann KA, Letvin NL, Zhou J, Hu S-L (1995) Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. AIDS Res Hum Retroviruses 11:963
102. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS (1996) Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type I in long-term nonprogressors. J Infect Dis 173:60
103. Morrow WJW, Wharton M, Stricker RB, Levy JA (1986) Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. Clin Immunol Immunopathol 40:515
104. Muller-Eberhard H (1988) Molecular organization and function of the complement system. Annu Rev Biochem 57:321
105. Nikolova EB, Tomana M, Russell MW (1994) All forms of human IgA antibodies bound to antigen interfere with complement (C3) fixation induced by IgG or antigen alone. Scand J Immunol 39:275
106. Nikolova EB, Tomana M, Russell MW (1994) The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human complement. Immunology 82:321
107. Nishanian P, Huskins KR, Stehn S, Detels R, Fahey JL (1990) A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 162:21
108. Pantaleo G, Fauci AS (1995) New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 13:487
109. Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza, Gantt K, Muro-Cacho C, Fauci AS (1994) Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 140:105
110. Pardo V, Aldana M, Colton RM, Fischl MA, Jaffe D, Moskowitz L, Hensley GT, Burgoignie J (1984) Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 101:429
111. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582
112. Perno C-F, Baseler MW, Broder S, Yarchoan R (1990) Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. J Exp Med 171:1043
113. Perricone R, Fontana L, De Carolis C, Carini C, Sirianni MC, Aiuti F (1987) Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphadenopathy syndrome (LAS). Clin Exp Immunol 70:500
114. Pinter C, Siccardi AG, Longhi R, Clivio A (1995) Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 11:577
115. Porterfield JS (1986) Antibody-dependent enhancement of viral infectivity. Adv Virus Res 31:335
116. Rademacher TW, Parekh RB, Dwek RA (1988) Glycobiology. Annu Rev Biochem 57:785
117. Ravetch JV, Kinet J-P (1991) Fc receptors. Annu Rev Immunol 9:457
118. Reisinger EC, Vogetseder W, Berzow D, Kofler D, Bitterlich G, Lehr HA, Wachter H, Dierich MP (1990) Complement-mediated enhancement of HIV-1-infection of the monoblastoid cell line U937. J Acquir Immune Defic Syndr 4:961
119. Reynes M, Aubert JP, Cohen JHM, Audouin J, Tricottet V, Diebold J, Kazatchkine MD (1985) Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 135:2687
120. Robinson WE, Montefiori DC, Mitchell WM (1988) Antibody-dependent enhancement of human immunodeficiency virus type I infection. Lancet I:790
121. Robinson WE, Montefiori DC, Gillespie DH, Mitchell WM (1989) Complement-mediated, antibody-dependent enhancement of HIV-1-infection in vitro is characterized by increased protein and RNA synthesis and infectious virus release. J Acquir Immune Defic Syndr 2:33
122. Robinson WE, Kawamura T, Lake D, Masuho Y, Mitchell WM, Hersh EM (1990) Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1-infection in vitro. J Virol 64:5301
123. Robinson WE, Montefiori DC, Mitchell WM (1990) Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 175:600
124. Robinson WE, Gorny MW, Xu J-Y, Mitchell WM, Zolla-Pazner S (1991) Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 65:4169
125. Ross GD, Medof E (1985) Membrane complement receptors specific for bound fragments of C3. Adv Immunol 37:217
126. Rosse WF (1987) The spleen as a filter. N Engl J Med 317:704
127. Rother RP, Rollins SA, Fodor WL, Albrecht J-C, Setter E, Fleckenstein B, Squinto SP (1994) Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri. J Virol 68:730
128. Russell MW, Mansa B (1989) Complement-fixing properties of human IgA antibodies. Scand J Immunol 30:175
129. Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT (1995) Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 182:501
130. Schifferli JA, Ng YC, Estreicher J, Walport MJ (1988) The clearance of tetanus toxoid-anti-tetanus toxoid immune complexes from the circulation of humans: complement- and erythrocyte CR1-dependent mechanisms. J Immunol 141:899
131. Schmitz J, Lunzen J van, Tenner-Racz K, Grosschupff G, Racz P, Schmitz H, Dietrich M, Hufert F (1994) Follicular dendritic cells (FDC) are not productively infected with HIV-1 in vivo. Adv Exp Med Biol 355:165
132. Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I, Schmitz H (1995) Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1-infection is controlled by CD55 and CD59. J Clin Invest 95:1520
133. Schumaker V, Calcott M, Spiegelberg H, Muller-Eberhard H (1976) Ultracentrifuge studies of the binding of IgG of different subclasses to the C1q subunit of the first component of complement. Biochemistry 15:5175
134. Schupbach J, Tomasik Z, Jendis J, Boni J, Seger R, Kind C (1994) IgG, IgM, and IgA response to HIV in infants born to HIV-1 infected mothers. J AIDS 7:421
135. Scott, ME, Landay AL, Lint TF, Spear GT (1993) In vivo decrease in the expression of complement receptor 2 on B-cells in HIV infection. J Acquir Immune Defic Syndr 7:37
136. Senaldi G, Peakman M, McManus T, Davies ET, Tee DEH, Vergani D (1990) Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis 162:1227
137. Senaldi G., Davies ET, Mahalingham M, Lu J, Pozniak A, Peakman M, Reid KBM, Vergani D (1995) Circulating levels of mannose binding protein in human immunodeficiency virus infection. J Infect 31:145
138. Serraino D, Salamina G, Franceschi S, Dubois D, La Vecchia C, Brunet JB, Ancelle-Park RA (1992) The epidemiology of AIDS-associated non-Hodgkin's lymphoma in the World Health Organization European Region. Br J Cancer 66:912
139. Shadduck PP, Weinberg JB, Haney AF, Bartlett JA, Langlois AJ, Bolognesi DP, Matthews TJ (1991) Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1-infection of human blood monocytes and peritoneal macrophages. J Virol 65:4309
140. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM (1992) Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 89:561
141. Siebelink KHJ, Tijhaar E, Huisman RC, Huisman W, Ronde A de, Darby IH, Francis MJ, Rimmelzwaan GF, Osterhaus ADME (1995) Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 69:3704
142. Smiley ML, Friedman HM (1985) Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells. J Virol 55:857
143. Soelder BM, Schultz TF, Hengster P, Lower J, Larcher C, Bitterlich G, Kurth R, Wachter H, Dierich MP (1989) HIV and HIV-infected cells differentially activate the human complement system independently of antibody. Immunol Lett 22:135
144. Soelder BM, Reisinger EC, Koefler D, Bitterlich G, Wachter H, Dierich MP (1989) Complement receptors: another port of entry for HIV. Lancet II:271
145. Spear GT, Jiang H, Sullivan BL, Gewurz H, Landay AL, Lint TF (1991) Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphoptropic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses 7:579
146. Spear GT, Takefman DM, Sullivan BL, Landay AL, Jennings MB, Carlson JR (1993) Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus. Virology 195:475
147. Spiegelberg HL (1974) Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol 19:259
148. Starcich BR, Hahn BH, Shaw GM, McNeely PD, Modrow S, Wolf H, Parks ES, Parks WP, Josephs SF, Gallo RC, Wong-Staal F (1986) Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45:637
149. Stein BS, Gowda SD, Lifson JD, Penhallow RC, Bensch KG, Engleman EG (1987) pH-independent HIV entry into CD4-positive cells via virus envelope fusion to the plasma membrane. Cell 49:659
150. Stoiber H, Pinter C, Siccardi AG, Clivio, A, Dierich MP (1996) Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 183:307
151. Suga T, Endoh M, Sakai H, Miura M, Tomino Y, Nomoto Y (1985) T-alpha cell subsets in human peripheral blood. 1989. J Immunol 134:1327
152. Sundquist V-A, Linde A, Kurth R, Werner A, Helm EB, Popovic M, Gallo RC, Wahren B (1986) Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis 153:970
153. Susal C, Kirschfink M, Kropelin M, Daniel V, Opelz G (1994) Complement activation by recombinant HIV-1 glycoprotein gp120. J Immunol 152:6028
154. Takeda A, Tuazon CU, Ennis FA (1988) Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242:580
155. Takeda A, Sweet RW, Ennis FA (1990) Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and FcγR. J Virol 64:5605
156. Tausk FA, McCutchan JA, Spechko P, Schreiber RD, Gigli I (1986) Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest 78:977
157. Tedder TF, Clement LY, Cooper MD (1984) Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J Immunol 133:678
158. Tew JG, Mandel TE (1978) The maintenance and regulation of serum antibody levels: evidence indicating a role for antigen retained in lymphoid follicles. J Immunol 120:1063
159. Theil S (1992) Mannan-binding protein, a complement activating animal lectin. Immunopharmacology 24:91
160. Theiler M, Smith HH (1937) The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65:787
161. Thieblemont N, Haeffner-Cavaillon N, Ledur A, L'age-Stehr J, Ziegler-Heitbrock HWL, Kazatchkine MD (1993) CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol 92:106
162. Thieblemont N, Haeffner-Cavaillon N, Weiss L, Maillet F, Kazatchkine MD (1993) Complement activation by gp160 glycoprotein of HIV-1. AIDS Res Hum Retroviruses 9:229
163. Thielens NM, Bally IM, Ebenbichler CF, Dierich, MP, Arlaud GJ (1993) Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. J Immunol 151:6583
164. Thyphronitis G, Kinoshita T, Inoue K, Schweinle JE, Tsokos GC, Mecalf ES, Finkelman FD, Balow JE (1991) Modulation of mouse complement receptors 1 and 2 suppresses antibody response in vivo. J Immunol 147:224
165. Toth FD, Mosborg-Petersen P, Kiss J, Aboagye-Mathiesen G, Zdravkovic M, Hager H, Aranyosi J, Lampe L, Ebbesen P (1994) Antibody-dependent enhancement of HIV-1-infection in human term syncytiotrophoblast cells cultured in vitro. Clin Exp Immunol 96:389
166. Tremblay M, Meloche S, Sekaly RP, Wainberg MA (1990) Complement receptor type 2 mediates enhancement of human immunodeficiency virus type 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med 171:1791
167. Trischmann H, Davis D, Lachmann PJ (1995) Lymphocytic strains of HIV-1 when complexed with enhancing antibodies can infect macrophages via FcγRIII, independently of CD4. AIDS Res Hum Retroviruses 11:343
168. Tsokos GC, Lambris JD, Finkelman FD, Anastassiou ED, June CH (1990) Monovalent ligands of complement receptor 2 inhibit, whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic-free calcium concentration. J Immunol 144:1640
169. Veronese FM, DeVico AL, Copeland TD, Droszland S, Gallo RC, Sarngadharan MG (1985) Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 229:1402
170. Wang S Z-S, Rushlow KE, Issel CJ, Cook RF, Cook SJ, Raabe ML, Chong Y-H, Costa L, Montelaro RC (1994) Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199:247
171. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson, JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117
172. Weiss L, Okada N, Haeffner-Cavaillon N, Hattori C, Faucher C, Kazatchkine MD, Okada H (1992) Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T-lymphocytes of HIV-infected patients. J Acquir Immune Defic Syndr 6:379
173. Wilson BS, Platt JL, Kay NE (1985) Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. Blood 66:824
174. Wu XS, Okada N, Iwamori M, Okada H (1996) IgM natural antibody against an asialo-oligosaccharide, gangliotetraose (GG4), sensitizes HIV-1-infected cells for cytolysis by homologous complement. Int Immunol 8:153
175. Yefenof E, Asjo B, Klein E (1991) Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivity. Int Immunol 3:395
176. Zeira M, Byrn RA, Groopman JE (1990) Inhibition of serum-enhanced HIV-1-infection of U937 monocytoid cells by recombinant soluble CD4 and anti-CD4 monoclonal antibody. AIDS Res Hum Retroviruses 6:629